The inhibition of the PI3K/AKT pathway, combined with the upregulation of the BAX/BCL2 ratio, collectively supports SSA’s pro-apoptotic and anti-tumor mechanisms, providing mechanistic evidence for its multi-targeted effects in prostate cancer treatment. The gene discussed is BAX; the disease is Familial prostate cancer.